Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | AURKA | O14965 | 14/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748457 | 0.88 | CHEK1 (0.79) | CHEK1EGFRAURKAMAP2K1KMT2A | |
| SCHEMBL2179113 | 0.86 | AURKA (0.56) | CHEK1EGFRAURKAMAP2K1KMT2A | |
| SCHEMBL6748458 | 0.84 | CHEK1 (0.60) | CHEK1EGFRAURKAMAP2K1KMT2A | |
| SCHEMBL6748470 | 0.83 | CHEK1 (0.71) | CHEK1EGFRAURKAMAP2K1KMT2A | |
| SCHEMBL12409613 | 0.78 | EGFR (0.48) | CHEK1EGFRAURKAKMT2AMEN1 | |
| SCHEMBL4699137 | 0.78 | CHEK1 (0.55) | CHEK1EGFRAURKAMAP2K1KMT2A | |
| SCHEMBL6748496 | 0.77 | AURKA (0.58) | CHEK1EGFRAURKAMAP2K1KMT2A | |
| SCHEMBL31061403 | 0.75 | CHEK1 (1.00) | CHEK1EGFRAURKAMAP2K1KMT2A | |
| SCHEMBL6748456 | 0.75 | CHEK1 (1.00) | CHEK1EGFRAURKAMAP2K1KMT2A | |
| SCHEMBL6748498 | 0.75 | EGFR (0.63) | EGFRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, PNPO, TPMT | CHEK1 969/4885EGFR 4423/4885AURKA 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.